2017

Muscular dystrophy meets protein biochemistry, the mother of invention

Steven D. Funk
Washington University School of Medicine in St. Louis

Jeffrey H. Miner
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/5751
Muscular dystrophy meets protein biochemistry, the mother of invention

Steven D. Funk and Jeffrey H. Miner
Department of Medicine, Division of Nephrology, Washington University School of Medicine, St. Louis, Missouri, USA.

Muscular dystrophies result from a defect in the linkage between the muscle fiber cytoskeleton and the basement membrane (BM). Congenital muscular dystrophy type MDC1A is caused by mutations in laminin α2 that either reduce its expression or impair its ability to polymerize within the muscle fiber BM. Defects in this BM lead to muscle fiber damage from the force of contraction. In this issue of the JCI, McKee and colleagues use a laminin polymerization–competent, designer chimeric BM protein in vivo to restore function of a polymerization-defective laminin, leading to normalized muscle structure and strength in a mouse model of MDC1A. Delivery of such a protein to patients could ameliorate many aspects of their disease.

Many pathways to muscular dystrophy

The mechanism whereby a contractile multinucleated skeletal muscle fiber is linked to the basement membrane (BM) that ensheaths it represents a paradigm for our understanding of BM assembly and interactions between the cell and extracellular matrix in the context of human pathobiology. Multiple matrix proteins, cell-surface receptors, transmembrane accessory proteins, cytoskeletal linker proteins, and glycosylating enzymes are required for the establishment and maintenance of the large, integrated complex that tightly links the myofiber cytoskeleton to the sarcolemma (plasma membrane) and the sarcolemma to the skeletal muscle BM (1). Genetic defects that alter the expression, structure, or function of these proteins cause a devastating class of diseases, the muscular dystrophies.

Muscular dystrophies are characterized by the progressive degeneration and weakness of skeletal muscle that includes muscle fiber necrosis, regeneration, and fibrosis (2). The severity and rate of progression of muscular dystrophy can vary dramatically, from congenital forms to the more common delayed-onset form known as Duchenne muscular dystrophy (3). From a cell biological perspective, muscular dystrophies with a genetic basis can be divided into types that correspond roughly to the site of the protein or protein complex that is affected by mutation. Mutations that affect the muscle BM cause congenital muscular dystrophy; those that affect the cytoskeletal protein dystrophin cause Duchenne and Becker muscular dystrophy; and those that affect transmembrane proteins called sarcoglycans cause limb-girdle muscular dystrophy (3). Interestingly, mutations that impact the enzymes responsible for glycosylation of dystroglycan cause the dystroglycanopathies, which manifest as muscular dystrophies with variable degrees of severity and timing of onset, as well as variable CNS and eye defects (4). Dystroglycan serves as the functional centerpiece of the dystrophin-glycoprotein complex that links the cytoskeleton to the BM and, therefore, plays a crucial role in maintaining skeletal muscle health (5).

Laminin and the basement membrane

Like all BMs, the skeletal muscle fiber BM contains specific isoforms from four major matrix protein families: laminins, type IV collagens, nidogens, and heparan sulfate proteoglycans. Laminins are large heterotrimeric glycoproteins composed of one α, one β, and one γ chain (6). The major laminin isoform of skeletal muscle BM is laminin α2β1γ1 (Lm211; Figure 1, left), while a structurally and functionally different isoform, laminin α5β2γ1, is found at the neuromuscular junction (7). Lm211 is a cruciform macromolecule that can self-polymerize in vitro to form a network via the formation of intermolecular ternary complexes involving the laminin N-terminal (LN) domain of each of the three chains (8). The unique C-terminus of the α2 chain, called the laminin globular (LG) domain, binds to receptors on the surface of the myofiber, including α-dystroglycan and integrin α7β1 (1). The binding of laminin to its receptors as muscle forms is thought to have a dual purpose: a) initiation of BM formation by concentrating the laminin at the cell surface above a critical concentration that promotes polymerization; and b) sending a signal to the cell (9). Upon maturation, laminin binding to its receptors links the muscle fiber to the BM, into which the laminin has become deeply integrated via direct and indirect interactions with nidogen, collagen IV, and proteoglycans.

Mutations in the laminin α2-encoding gene (LAMA2) cause congenital muscular dystrophy. Mutations that prevent production of the protein typically (though not always) cause more severe disease than do missense mutations, internal deletions, or mutations that reduce Lm211 protein levels (1) (Figure 1, middle). The existence of several naturally occurring and engineered mouse models with Lama2 mutations with features of human congenital muscular dystrophy have been instrumental for investigating pathogenic mechanisms and potential treatments for both severe and milder forms of the disease (10).

Biochemistry and protein therapy

The current work by McKee et al. in this issue (11) and previous studies have exploit-
ed the intermolecular interactions among BM proteins and their cognate receptors that have been deciphered through decades of basic science research. In addition to laminin-receptor interactions, laminins are secondarily and indirectly linked to cell-surface receptors by the heparan sulfate proteoglycan agrin, which binds to the LMγ1-coiled-coil region via its N-terminal agrin domain as well as to dystroglycan and integrins via its C-terminal LG-like domains (12). Furthermore, the laminin network is linked to the type IV collagen network by nidogen, which binds to the short arm LE3b via the G2 domain, and to a region in collagen IV near the C-terminal noncollagenous 1 (NC1) domain via nidogen’s G2 domain (13).

Previously, research teams led by Ruegg tested a molecular therapy in severe forms of congenital muscular dystrophy, in which LMα2 is either truncated and expressed at very low levels (dyr/dy2r mice) or completely missing (dy12/dy12 mice). These mice and patients who lack LMα2 exhibit increased LMα4- and LMα5-containing trimers, but decreased α-dystroglycan expression. Although these laminins have poor muscle-specific receptor binding, and LMα4 lacks the LN domain required for polymerization, Ruegg and colleagues hypothesized that a mini-agrin protein containing only the LN domain of the laminin α1-subunit and the G2–G3 domains of nidogen, which simultaneously rescued polymerization of mutant truncated laminin α2/αLm211 (right) and linked laminin to the collagen IV network (not depicted). αLNNd thereby restored muscle function in dy2r/dy2r mice.

Figure 1. A designer chimeric polypeptide restores function of defective laminin. Lm211 is a heterotrimeric glycoprotein consisting of one α2-, one β1-, and one γ1-subunit that is an essential extracellular matrix component of the skeletal muscle fiber BM. WT Lm211 readily polymerizes and becomes integrated into the BM and serves to link the muscle fiber to the BM via receptor binding. Mutations in the gene encoding the laminin α2-subunit cause a congenital muscular dystrophy due to absent or defective Lm211. The mutant Lm211 present in dy2r/dy2r mice has a truncated laminin α2 that is unable to polymerize. The polymerization defect results in disruption of the BM, leading to loss of BM integrity and reduced muscle function. In this issue, McKee and colleagues developed a chimeric polypeptide (αLNNd) that contains the laminin N-terminal (LN) domain of the laminin α1-subunit and the G2–G3 domains of nidogen, which simultaneously rescued polymerization of mutant truncated laminin α2/αLm211 (right) and linked laminin to the collagen IV network (not depicted). αLNNd thereby restored muscle function in dy2r/dy2r mice.

The αLNNd protein is composed of the LMα1 LN and LEa1-4 domains fused to the G2–G3 portions of nidogen, thereby replacing the nidogen G1 domain and short segment that connects G1 to the G2–G3 segment with the LMα1 N-terminal domain. The nidogen portion binds to LMγ1 LE3b via the G3 domain and to the collagen type IV network via the G2 domain, thereby preserving the laminin-collagen linkage. Biochemical studies and naturally existing laminin heterotrimer combinations (Lm111, Lm211) prove that both LMα1 and LMα2 LN domains facilitate polymerization through interactions with LMβ1 and LMγ1 LN domains. Additionally, both overexpression and exogenous provision of Lm111 can ameliorate muscular dystrophy in Lama2-mutant mice (18, 19). Thus, the LMα1 LN domain of αLNNd readily substitutes for the missing LMα2 LN domain both in vivo and in vitro (11). This chimeric protein corrects the polymerization defect in dy2r/dy2r mice (Figure 1, right) (and should presumably do the same in LMα2 polymerization-defective patients), thereby reinforcing the concept that laminin polymerization is critical for maintaining BM integrity. Moreover, like the effects of the mini-agrin protein in the dy2r/dy2r and dy12/dy12 models, the αLNNd chimera restored muscle performance in dy2r/dy2r animals to a level similar to that of congenital muscular dystrophy, in which

Crichton et al. (14, 15) tested a molecular therapy in severe forms of congenital muscular dystrophy, in which

Patients who harbor mutations that only affect the LMα2 LN domain have mild phenotypes compared with those with mutations that result in total loss of LMα2 (16), similar to missense mutations in the LMβ2 LN domain that affect the kidney glomerular BM of Pierson syndrome spectrum patients (17). On the basis of biochemical studies, LN domain mutations in LMβ2 and LMα2 are predicted to confer some degree of laminin polymerization defects. For LMα2, these are collectively modeled by dy2r/dy2r mice that lack the LMα2 LN domain; but, unlike dy2r/dy2r mice, dy2r/dy2r mice show only a modest decrease in LMα2 protein levels. McKee et al. exploited the laminin-nidogen-collagen linkage to explore the therapeutic efficacy of a chimeric fusion protein, αLNNd, via transgenic expression in skeletal muscle of dy2r/dy2r mice.
of control animals and normalized most histopathological parameters. αLNNd also normalized mutant LMα2 and LMγ1 protein levels in vivo to those of control mice and restored polymerization of the mutant Lm211 on the surface of cultured cells, indicating that the fusion protein behaved as predicted.

Prospects for the future
There are currently no effective treatments for muscular dystrophies. Experimental studies reveal that pharmaceutical modulation of some basic physiological and cell biological processes, including inflammation, fibrosis, apoptosis, and regeneration, may improve patients’ phenotypes (1). In parallel, we summarize here exciting, basic science–driven molecular modulations that address the matrix protein deficiencies underlying congenital muscular dystrophies. Although McKee et al. did not investigate inducible rescue with αLNNd, which would better mimic attempted therapy in a clinical context, the efficacy of induced expression of mini-agrin (20) indicates that dyγ2/dyδ2 phenotypes would likely be improved by late therapeutic intervention. In addition, Qiao et al. demonstrated that expression of a mini-agrin cDNA packaged into an adeno-associated virus that can either be directly injected into muscles or delivered systemically improves phenotypes in mice (21). Interestingly, αLNNd did not interfere with WT Lm111 polymerization in assays on myotubes in vitro (11), suggesting that this fusion protein does not perturb normal BM integrity in vivo. We would further suggest that the combination of mini-agrin and αLNNd may have synergistic effects by enhancing dystroglycan binding of an αLNNd-stabilized LMα4 network, the most highly compensating laminin in patients and mice lacking LMα2. The study by Mckee et al. indicates that functional designer molecules, potentially in combination with suitable delivery systems and pharmaceutical strategies (1), hold promise as future therapeutics for congenital muscular dystrophy. Importantly, the small sizes of αLNNd (157 kDa) and mini-agrin (106 kDa) relative to the affected 341-kDa LMα2 chain and the approximately 750-kDa Lm211 trimmer, together with the fact that αLNNd and mini-agrin function as monomers, make them well suited for therapeutic intervention, whether delivered as naked or virally encoded proteins.

Acknowledgments
The authors were supported by NIH grants R01DK078314 and T32DK007126.

Address correspondence to: Jeffrey H. Miner, Division of Nephrology, Washington University School of Medicine, 4523 Clayton Ave., St. Louis, Missouri 63110, USA. Phone 314.362.8235; E-mail: minerj@wustl.edu.